Monte Rosa Therapeutics, Inc.
GLUE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $76 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $8 | $6 | $0 | $0 |
| Gross Profit | $68 | -$6 | $0 | $0 |
| % Margin | 89.3% | – | – | – |
| R&D Expenses | $122 | $105 | $85 | $57 |
| G&A Expenses | $35 | $32 | $27 | $16 |
| SG&A Expenses | $35 | $32 | $27 | $16 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$8 | $0 | $0 | $0 |
| Operating Expenses | $149 | $137 | $112 | $73 |
| Operating Income | -$81 | -$143 | -$112 | -$73 |
| % Margin | -107.3% | – | – | – |
| Other Income/Exp. Net | $11 | $8 | $4 | -$1 |
| Pre-Tax Income | -$70 | -$135 | -$109 | -$74 |
| Tax Expense | $3 | $0 | $0 | $0 |
| Net Income | -$73 | -$135 | -$109 | -$74 |
| % Margin | -96.1% | – | – | – |
| EPS | -0.98 | -2.63 | -2.3 | -1.59 |
| % Growth | 62.7% | -14.3% | -44.7% | – |
| EPS Diluted | -0.98 | -2.63 | -2.3 | -1.59 |
| Weighted Avg Shares Out | 74 | 51 | 47 | 47 |
| Weighted Avg Shares Out Dil | 74 | 51 | 47 | 47 |
| Supplemental Information | – | – | – | – |
| Interest Income | $11 | $9 | $4 | $0 |
| Interest Expense | $0 | $0 | $4 | $0 |
| Depreciation & Amortization | $8 | $6 | $4 | $2 |
| EBITDA | -$73 | -$137 | -$109 | -$71 |
| % Margin | -96.5% | – | – | – |